Skip to main content

Aspira Women's Health Inc.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

AWHL$0.430.0%Stored close · as of Sep 19, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page hereto)

POWER OF ATTORNEY

Each of the undersigned officers and directors of Aspira Women’s Health Inc., hereby constitutes and appoints Michael Buhle and James Crawford, and each or any of them, as their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

NameTitleDate
/s/ Michael BuhlePresident and Chief Executive Officer
Michael Buhle(Principal Executive Officer) and DirectorMarch 27, 2025
/s/ James CrawfordVice President of Finance
James Crawford(Principal Financial Officer and Principal Accounting Officer)March 27, 2025
/s/ Jannie HerchukChair of the Board of DirectorsMarch 27, 2025
Jannie Herchuk
/s/ Ellen BeausangDirectorMarch 27, 2025
Ellen Beausang
/s/ Stefanie CavanaughDirectorMarch 27, 2025
Stefanie Cavanaugh
/s/ Celeste FralickDirectorMarch 27, 2025
Celeste Fralick
/s/ Ellen O’Connor-VosDirectorMarch 27, 2025
Ellen O’Connor-Vos
/s/ Winfred ParnellDirectorMarch 27, 2025
Winfred Parnell
/s/ John RagardDirectorMarch 27, 2025
John Ragard
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.